VBI Vaccines Inc (NASDAQ:VBIV)’s share price dropped 5.4% on Thursday . The stock traded as low as $2.08 and last traded at $2.12. Approximately 574,982 shares traded hands during trading, an increase of 165% from the average daily volume of 216,720 shares. The stock had previously closed at $2.24.

VBIV has been the topic of several research analyst reports. Zacks Investment Research cut VBI Vaccines from a “hold” rating to a “sell” rating in a report on Friday, September 28th. BMO Capital Markets decreased their target price on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $9.08.

The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 0.14.

VBI Vaccines (NASDAQ:VBIV) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.09). VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%. The company had revenue of $0.23 million during the quarter. On average, equities research analysts anticipate that VBI Vaccines Inc will post -0.94 EPS for the current fiscal year.

In related news, CEO Jeff Baxter bought 13,500 shares of the firm’s stock in a transaction that occurred on Friday, August 3rd. The shares were bought at an average cost of $2.01 per share, with a total value of $27,135.00. Following the acquisition, the chief executive officer now owns 224,905 shares in the company, valued at $452,059.05. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders purchased 40,400 shares of company stock worth $85,092. 54.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Paloma Partners Management Co bought a new stake in VBI Vaccines during the second quarter valued at about $254,000. Altshuler Shaham Ltd raised its holdings in VBI Vaccines by 11.5% during the second quarter. Altshuler Shaham Ltd now owns 891,442 shares of the biopharmaceutical company’s stock valued at $2,452,000 after acquiring an additional 91,800 shares during the period. Jane Street Group LLC bought a new stake in VBI Vaccines during the second quarter valued at about $331,000. Alpine Global Management LLC bought a new stake in VBI Vaccines during the second quarter valued at about $222,000. Finally, Menora Mivtachim Holdings LTD. raised its holdings in VBI Vaccines by 27.4% during the second quarter. Menora Mivtachim Holdings LTD. now owns 3,459,868 shares of the biopharmaceutical company’s stock valued at $9,515,000 after acquiring an additional 744,706 shares during the period. 47.99% of the stock is currently owned by institutional investors and hedge funds.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

See Also: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.